On May 25, Humanwell Healthcare issued an announcement that its wholly-funded branch company Humanwell Healthcare USA has paid the full stock right transfer sum of $550 million and finished the share and ownership transfer procedures for Pharma and its related enterprise RE Holdco. The two companies became wholly-funded branch companies of Humanwell Healthcare and will be included into the consolidated scope of the company.

According to announcements issued by Humanwell Healthcare, the purchase price of Pharma and RE Holdco are $529 million and $21 million, respectively. The two companies were purchased with 100 percent of the stock rights.

EpicPharma is a medicine enterprise covering R&D, production, and sales. It has the production qualifications for prescribed medicines. This company is currently in the production and distribution operations for generic drugs. Its main products are all prescription medicines targeted at adaption diseases such as gall-stones, pain, motion sickness, and high blood pressure.

In addition, the company has over 30 R&D projects at different stages. Its R&D products are mainly focused in subdivided fields such as anaesthetic pain relief, nerve and high blood pressure, and controlled-sustained agents. More than 10 varieties are applying for approval from the FDA. The declaration breed oxycodone controlled release tablet is under the patent protection period. The patent challenge for Epic Pharma has succeeded, which is predicted to be approved in 2018. At present, the US market scale of for oxycodone controlled release tablet in 2015 was around $2.3 billion.

Up to Dec 31, 2015, the total sum of a consolidated sheet of Pharma and RE Holdco reached $67.56 million, while the total debt were $30 million, the net assets were $37.39 million, the operating receipt was $118 million, and the net profit was $57.63 million.